Investors sentiment increased to 1.65 in Q3 2017. Its up 0.24, from 1.41 in 2017Q2. It is positive, as 16 investors sold IMMU shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported. Boston Private Wealth Ltd Liability Corp reported 145,000 shares stake. Tower Capital Ltd Liability Corporation (Trc), a New York-based fund reported 2,723 shares. Moreover, Suntrust Banks Inc has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 28,400 shares. Art Advisors Ltd Llc holds 0.09% or 122,500 shares. Ra Mgmt Ltd Liability Company accumulated 1.48M shares or 1.87% of the stock. The Illinois-based Northern Trust has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). 4.67M were reported by Vanguard. State Board Of Administration Of Florida Retirement Sys owns 81,067 shares or 0% of their US portfolio. The New York-based Jennison Associates Limited Liability Company has invested 0.03% in Immunomedics, Inc. (NASDAQ:IMMU). Trexquant Lp invested in 79,923 shares or 0.28% of the stock. Rhenman & Prns Asset Management invested in 500,000 shares or 0.89% of the stock. Pnc Financial Services Gp Inc reported 1,721 shares. Balyasny Asset Limited Liability Com accumulated 0.01% or 235,687 shares. Noven Gp has invested 0.12% in Immunomedics, Inc. (NASDAQ:IMMU). Atika Mngmt Limited Liability, a New York-based fund reported 135,000 shares.
Since August 21, 2017, it had 0 buys, and 6 sales for $2.10 million activity. GOLDENBERG CYNTHIA L sold $369,426 worth of Immunomedics, Inc. (NASDAQ:IMMU) on Monday, August 21.
Ken Greenberg increased its stake in Immunomedics Inc (IMMU) by 62.25% based on its latest 2017Q3 regulatory filing with the SEC. Ghost Tree Capital Llc bought 746,946 shares as the company’s stock rose 37.64% with the market. The hedge fund run by Ken Greenberg held 1.95 million shares of the health care company at the end of 2017Q3, valued at $27.22M, up from 1.20 million at the end of the previous reported quarter. Ghost Tree Capital Llc who had been investing in Immunomedics Inc for a number of months, seems to be bullish on the $2.49B market cap company. The stock decreased 1.40% or $0.22 during the last trading session, reaching $15.5. About 2.19M shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since January 8, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.
Ghost Tree Capital Llc, which manages about $470.91 million US Long portfolio, decreased its stake in Insmed Inc (NASDAQ:INSM) by 150,600 shares to 324,400 shares, valued at $10.13M in 2017Q3, according to the filing. It also reduced its holding in Puma Biotechnology Inc (NYSE:PBYI) by 85,000 shares in the quarter, leaving it with 65,000 shares, and cut its stake in Nevro Corp.
Another recent and important Immunomedics, Inc. (NASDAQ:IMMU) news was published by Globenewswire.com which published an article titled: “Immunomedics to Present at the 36th Annual JP Morgan Healthcare Conference” on January 04, 2018.
Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage
Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics has $16 highest and $1.50 lowest target. $15.50’s average target is 0.00% above currents $15.5 stock price. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Wednesday, August 16 by Cowen & Co. The stock has “Buy” rating by Jefferies on Tuesday, September 19. The firm earned “Buy” rating on Monday, October 9 by Jefferies. Wells Fargo downgraded the stock to “Market Perform” rating in Tuesday, June 21 report. The rating was upgraded by Jefferies to “Buy” on Friday, May 6. The rating was maintained by Jefferies with “Hold” on Tuesday, March 15. The company was maintained on Monday, July 24 by Cowen & Co. As per Friday, December 4, the company rating was downgraded by Wells Fargo. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Wednesday, December 6 by Cowen & Co. The rating was maintained by Jefferies on Wednesday, December 6 with “Buy”.